Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

(OSKIRA-Asia-1X): A Long-term Study to Assess the Safety of Fostamatinib in the Treatment of Rheumatoid Arthritis in Asia

NCT01640054 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01640054
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01640054 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
(OSKIRA-Asia-1X): A Long-term Study to Assess the Safety of Fostamatinib in the Treatment of Rheumatoid Arthritis in Asia
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2012
Completion date
July 31, 2013
Enrollment
115 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis